Consensus guidelines for the detection of immunogenic cell death

OncoImmunology

Volumn 3, Issue 9, 2014, Pages

  Kepp, Oliver ^a,b,c   Tartour, Eric ^b,bm   Vitale, Ilio ^d   Vacchelli, Erika ^a,b,c   Adjemian, Sandy ^a,b,c,e   Agostinis, Patrizia ^f   Apetoh, Lionel ^g,h,i   Aranda, Fernando ^a,b,c   Barnaba, Vincenzo ^j,k   Bloy, Norma ^a,b,c   Bracci, Laura ^l   Breckpot, Karine ^m   Brough, David ⁿ   Buqué, Aitziber ^a,b,c   Castro, Maria G ^o   Cirone, Mara ^j   Colombo, Maria I ^p   Cremer, Isabelle ^a,b,q   Demaria, Sandra ^r   Dini, Luciana ^s   Eliopoulos, Aristides G ^t,u   Faggioni, Alberto ^j   Formenti, Silvia C ^r   Fučíková, Jitka ^v,w   Gabriele, Lucia ^l   Gaipl, Udo S ^x   Galon, Jérôme ^a,b,q,y   Garg, Abhishek ^f   Ghiringhelli, François ^g,h,i   Giese, Nathalia A ^z   Guo, Zong Sheng ^aa   Hemminki, Akseli ^ab   Herrmann, Martin ^ac   Hodge, James W ^ad   Holdenrieder, Stefan ^ae   Honeychurch, Jamie ⁿ   Hu, Hong Min ^af,ag   Huang, Xing ^a,b,c   Illidge, Tim M ⁿ   Kono, Koji ^ah,ai   Korbelik, Mladen ^aj   Krysko, Dmitri V ^ak,al   Loi, Sherene ^am   Lowenstein, Pedro R ^o   Lugli, Enrico ^an,ao   Ma, Yuting ^a,b,c   Madeo, Frank ^ap   Manfredi, Angelo A ^aq,ar   Martins, Isabelle ^c,as,at   Mavilio, Domenico ^an,ao   Menger, Laurie ^a,b,c,au   Merendino, Nicolò ^av   Michaud, Michael ^a,b,c   Mignot, Gregoire ^aw   Mossman, Karen L ^ax,ay   Multhoff, Gabriele ^az   Oehler, Rudolf ^ba   Palombo, Fabio ^j,k   Panaretakis, Theocharis ^bb   Pol, Jonathan ^a,b,c   Proietti, Enrico ^l   Ricci, Jean Ehrland ^bc,bd,be   Riganti, Chiara ^bf   Rovere Querini, Patrizia ^aq,ar   Rubartelli, Anna ^bg   Sistigu, Antonella ^d   Smyth, Mark J ^bh,bi   Sonnemann, Juergen ^bj   Spisek, Radek ^v,w   Stagg, John ^bk   Sukkurwala, Abdul Qader ^a,b,c,bl   Thorburn, Andrew ^bn   Thorne, Stephen H ^aa   Vandenabeele, Peter ^ak,al   Velotti, Francesca ^av   Workenhe, Samuel T ^ax,ay   Yang, Haining ^bo   Zong, Wei Xing ^bp   Zitvogel, Laurence ^b,c,bq   Kroemer, Guido ^a,b,c,y,bm   Galluzzi, Lorenzo ^a,b,c,y   more..

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^g Institut Médical de Génétique et d Immunologie   (France)

^h CENTRE GEORGES FRANÇOIS LECLERC   (France)

ⁱ UNIVERSITÉ DE BOURGOGNE   (France)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k Pasteur Institute   (Italy)

^l ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^m VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

^o UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^p Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^q SORBONNE UNIVERSITÉ   (France)

^r NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s UNIVERSITY OF SALENTO   (Italy)

^t UNIVERSITY OF CRETE   (Greece)

^u INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

^v UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^w Sotio   (Czech Republic)

^x UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^y UNIVERSITÉ PARIS DESCARTES   (France)

^z UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^aa UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^ab UNIVERSITY OF HELSINKI   (Finland)

^ac UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^ad NATIONAL CANCER INSTITUTE   (United States)

^ae UNIVERSITY HOSPITAL BONN   (Germany)

^af Nanjing Second Hospital   (China)

^ag PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^ah NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^ai NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^aj BRITISH COLUMBIA CANCER AGENCY   (Canada)

^ak DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^al GHENT UNIVERSITY   (Belgium)

^am PETER MACCALLUM CANCER CENTRE   (Australia)

^an HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^ao UNIVERSITY OF MILAN   (Italy)

^ap UNIVERSITY OF GRAZ   (Austria)

^aq VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^ar SAN RAFFAELE HOSPITAL   (Italy)

^as Institut Gustave Roussy   (France)

^at UNIVERSITÉ PARIS SACLAY   (France)

^au UNIVERSITY COLLEGE LONDON   (United Kingdom)

^av UNIVERSITY OF TUSCIA   (Italy)

^aw UNIVERSITÉ DE NANTES   (France)

^ax MCMASTER UNIVERSITY   (Canada)

^ay MCMASTER UNIVERSITY   (Canada)

^az TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^ba MEDICAL UNIVERSITY OF VIENNA   (Austria)

^bb KAROLINSKA INSTITUTE   (Sweden)

^bc CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^bd UNIVERSITÉ CÔTE D'AZUR   (France)

^be UNIVERSITY HOSPITAL OF NICE   (France)

^bf UNIVERSITY OF TURIN   (Italy)

^bg UNIVERSITY OF GENOA   (Italy)

^bh QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^bi UNIVERSITY OF QUEENSLAND   (Australia)

^bj JENA UNIVERSITY HOSPITAL   (Germany)

^bk UNIVERSITÉ DE MONTRÉAL   (Canada)

^bl DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^bm HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^bn UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^bo UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^bp STONY BROOK UNIVERSITY   (United States)

^bq Centre d'Investigations Cliniques Biothérapies 507   (France)

more..

Author keywords

ATP release; Autophagy; Calreticulin; Endoplasmic reticulum stress; HMGB1; Immunotherapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALRETICULIN; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MITOXANTRONE; PATTERN RECOGNITION RECEPTOR; PROTEIN BAX; SYNAPTOBREVIN 1; TOLL LIKE RECEPTOR 4; X BOX BINDING PROTEIN 1;

AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL DEATH; CELL MEMBRANE PERMEABILITY; CONSENSUS; DISEASE MARKER; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOBLOTTING; IMMUNOSTIMULATION; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR VOLUME;

EID: 84923247523     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.955691     Document Type: Review

References (288)

1. Galluzzi L, MaiuriMC, Vitale I, ZischkaH, CastedoM, Zitvogel L, Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007; 14: 1237-43; PMID: 17431418; http://dx. doi. org/10. 1038/sj. cdd. 4402148.
2. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, et al. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ 2009; 16: 3-11; PMID: 18846107; http://dx. doi. org/10. 1038/cdd. 2008. 150.
3. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, et al. Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012. Cell Death Differ 2012; 19: 107-20; PMID: 21760595; http://dx. doi. org/10. 1038/cdd. 2011. 96.
4. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-14; PMID: 20823910; http://dx. doi. org/10. 1038/nrm2970.
5. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 2014; 15: 135-47; PMID: 24452471; http://dx. doi. org/10. 1038/nrm3737.
6. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72; PMID: 23157435; http://dx. doi. org/10. 1146/annurev-immunol-032712-100008.
7. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860-75; PMID: 23151605; http://dx. doi. org/10. 1038/nrc3380.
8. Vogt CI. Untersuchungen über die Entwicklungsgeschichte der Geburtshelferkröte (Alytes obstetricans). Jent, 1842.
9. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009; 16: 1093-107; PMID: 19373242; http://dx. doi. org/10. 1038/cdd. 2009. 44.
10. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014; 5: e1257; PMID: 24874729; http://dx. doi. org/10. 1038/cddis. 2013. 428.
11. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57; PMID: 4561027; http://dx. doi. org/10. 1038/bjc. 1972. 33.
12. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115: 2679-88; PMID: 16200202; http://dx. doi. org/10. 1172/JCI26390.
13. Ericsson JL. Studies on induced cellular autophagy. I. Electron microscopy of cells with in vivo labelled lysosomes. Exp Cell Res 1969; 55: 95-106; PMID: 5780799; http://dx. doi. org/10. 1016/0014-4827(69)90462-5.
14. Maximow AA. Studies on the Changes Produced by Roentgen Rays in Inflamed Connective Tissue. J Exp Med 1923; 37: 319-40; PMID: 19868729; http://dx. doi. org/10. 1084/jem. 37. 3. 319.
15. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4: 151-75; PMID: 18188003; http://dx. doi. org/10. 4161/auto. 5338.
16. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545-56; PMID: 7595224; http://dx. doi. org/10. 1084/jem. 182. 5. 1545.
17. TaitSW, GreenDR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621-32; PMID: 20683470; http://dx. doi. org/10. 1038/nrm2952.
18. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163; PMID: 17237344; http://dx. doi. org/10. 1152/physrev. 00013. 2006.
19. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9: 231-41; PMID: 18073771; http://dx. doi. org/10. 1038/nrm2312.
20. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005; 6: 328-40; PMID: 15803139; http://dx. doi. org/10. 1038/nrm1619.
21. Galluzzi L, Kepp O, Krautwald S, Kroemer G, Linkermann A. Molecular mechanisms of regulated necrosis. Semin Cell Dev Biol 2014; 35C: 24-32; PMID 24582829; http://dx. doi: 10. 1016/j. semcdb. 2014. 02. 006.
22. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-701; PMID: 16365148; http://dx. doi. org/10. 1084/jem. 20050915.
23. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, Gonnella R, Frati L, Faggioni A. Activation of dendritic cells by tumor cell death. Oncoimmunology 2012; 1: 1218-9; PMID: 23170286; http://dx. doi. org/10. 4161/onci. 20428.
24. Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol 2006; 27: 244-50; PMID: 16584921; http://dx. doi. org/10. 1016/j. it. 2006. 03. 005.
25. Abud HE. Shaping developing tissues by apoptosis. Cell Death Differ 2004; 11: 797-9; PMID: 15167902; http://dx. doi. org/10. 1038/sj. cdd. 4401455.
26. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, Kirchner T, Kalden JR, Herrmann M. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 191-201; PMID: 11817590; http://dx. doi. org/10. 1002/1529-0131(200201)46: 1<191:: AIDART10027>3. 0. CO; 2-K.
27. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010; 6: 280-9; PMID: 20431553; http://dx. doi. org/10. 1038/nrrheum. 2010. 46.
28. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, KroemerG. Trial watch: chemotherapywith immunogenic cell death inducers. Oncoimmunology 2012; 1: 179-88; PMID: 22720239; http://dx. doi. org/10. 4161/onci. 1. 2. 19026.
29. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2: e23510; PMID: 23687621; http://dx. doi. org/10. 4161/onci. 23510.
30. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3: e27878; PMID: 24800173; http://dx. doi. org/10. 4161/onci. 27878.
31. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71: 4809-20; PMID: 21646474; http://dx. doi. org/10. 1158/0008-5472. CAN-11-0753.
32. Cirone M, Garufi A, Di Renzo L, Granato M, Faggioni A, D'Orazi G. Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells. Oncoimmunology 2013; 2: e26198; http://dx. doi. org/10. 4161/onci. 26198.
33. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014; 21: 15-25; PMID: 23787994; http://dx. doi. org/10. 1038/cdd. 2013. 67.
34. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61; PMID: 17187072; http://dx. doi. org/10. 1038/nm1523.
35. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, Splısek R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71: 4821-33; PMID: 21602432; http://dx. doi. org/10. 1158/0008-5472. CAN-11-0950.
36. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578-90; PMID: 19165151; http://dx. doi. org/10. 1038/emboj. 2009. 1.
37. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15: 1499-509; PMID: 18464797; http://dx. doi. org/10. 1038/emboj. 2009. 1x.
38. Bugaut H, Bruchard M, Berger H, Derangere V, Odoul L, Euvrard R, Ladoire S, Chalmin F, Véegran F, Réebée C, et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS One 2013; 8: e65181; PMID: 23762310; http://dx. doi. org/10. 1371/journal. pone. 0065181.
39. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-91; PMID: 19881547; http://dx. doi. org/10. 1038/onc. 2009. 356.
40. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147-58; PMID: 21151176; http://dx. doi. org/10. 1038/onc. 2010. 500.
41. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9; PMID: 17704786; http://dx. doi. org/10. 1038/nm1622.
42. Gou HF, Huang J, Shi HS, Chen XC, Wang YS. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. PLoS One 2014; 9: e85789; http://dx. doi. org/10. 1371/journal. pone. 0085789.
43. Tongu M, Harashima N, Yamada T, Harada T, Harada M. Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother 2010; 59: 769-77; PMID: 19940990; http://dx. doi. org/10. 1007/s00262-009-0797-1.
44. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71: 768-78; PMID: 21156650; http://dx. doi. org/10. 1158/0008-5472. CAN-10-2788.
45. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011; 33: 369-83; PMID: 21611872; http://dx. doi. org/10. 1007/s00281-011-0245-0.
46. Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, et al. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol 2013; 34: 81-90; PMID: 22983919; http://dx. doi. org/10. 1007/s13277-012-0513-1.
47. Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, Wakefield LM, Oppenheim JJ. Effective chemoimmunotherapy with anti-TGFbeta antibody and cyclophosphamide in a mouse model of breast cancer. PLoS One 2014; 9: e85398; PMID: 24416401; http://dx. doi. org/10. 1371/journal. pone. 0085398.
48. Guerriero JL, Ditsworth D, Fan Y, Zhao F, Crawford HC, Zong WX. Chemotherapy induces tumor clearance independent of apoptosis. Cancer Res 2008; 68: 9595-600; PMID: 19047135; http://dx. doi. org/10. 1158/0008-5472. CAN-08-2452.
49. Beneteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA, Marchetti S, Cornille A, Carles M, Ricci JE. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc Natl Acad Sci U S A 2012; 109: 20071-6; PMID: 23169636; http://dx. doi. org/10. 1073/pnas. 1206360109.
50. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013; 12: 829-46; PMID: 24113830; http://dx. doi. org/10. 1038/nrd4145.
51. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68: 5301-8; PMID: 18593931; http://dx. doi. org/10. 1158/0008-5472. CAN-08-0237.
52. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337: 1678-84; PMID: 23019653; http://dx. doi. org/10. 1126/science. 1224922.
53. Pellicciotta I, Yang CP, Goldberg GL, Shahabi S. Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells. Gynecol Oncol 2011; 122: 625-31; PMID: 21621254; http://dx. doi. org/10. 1016/j. ygyno. 2011. 05. 007.
54. Dutcher JD, Vonsaltza MH, Pansy FE. Septacidin, a new antitumor and antifungal antibiotic produced by streptomyces fibriatus. Antimicrob Agents Chemother (Bethesda) 1963; 161: 83-8; PMID: 14275007.
55. Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckenstuhl C, Durchschlag M, Michaud M, Senovilla L, Sistigu A, Ma Y, et al. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ 2014; 21: 59-68; PMID: 23787997; http://dx. doi. org/10. 1038/cdd. 2013. 73.
56. Perez CA, Fu A, Onishko H, Hallahan DE, Geng L. Radiation induces an antitumour immune response to mouse melanoma. Int J Radiat Biol 2009; 85: 1126-36; PMID: 19995238; http://dx. doi. org/10. 3109/09553000903242099.
57. Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, KroemerG, Galluzzi L. Trial watch: anticancer radioimmunotherapy. Oncoimmunology 2013; 2: e25595; PMID: 24319634; http://dx. doi. org/10. 4161/onci. 25595.
58. Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2013; 2: e26536; PMID: 24404424; http://dx. doi. org/10. 4161/onci. 26536.
59. Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, Murata K, Fujii H, Nakano T, Kono K. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 2012; 72: 3967-76; PMID: 22700877; http://dx. doi. org/10. 1158/0008-5472. CAN-12-0851.
60. Ko A, Kanehisa A, Martins I, Senovilla L, Chargari C, Dugue D, Mariñno G, Kepp O, Michaud M, Perfettini JL, et al. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ 2014; 21: 92-9; PMID: 24037090; http://dx. doi. org/10. 1038/cdd. 2013. 124.
61. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012; 84: 879-80; PMID: 23078897; http://dx. doi. org/10. 1016/j. ijrobp. 2012. 06. 020.
62. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2014; 5: 403-16; PMID: 24480782.
63. Schildkopf P, Frey B, Ott OJ, Rubner Y, Multhoff G, Sauer R, Fietkau R, GaiplUS. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother Oncol 2011; 101: 109-15; PMID: 21704416; http://dx. doi. org/10. 1016/j. radonc. 2011. 05. 056.
64. Gorin JB, Menager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Chéerel M, Davodeau F, et al. Antitumor immunity induced after alpha irradiation. Neoplasia 2014; 16: 319-28; PMID: 24862758; http://dx. doi. org/10. 1016/j. neo. 2014. 04. 002.
65. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 2012; 61: 215-21; PMID: 22193987; http://dx. doi. org/10. 1007/s00262-011-1184-2.
66. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-79; PMID: 22252128; http://dx. doi. org/10. 1038/emboj. 2011. 497.
67. Galluzzi L, Kepp O, Kroemer G. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J 2012; 31: 1055-7; PMID: 22252132; http://dx. doi. org/10. 1038/emboj. 2012. 2.
68. Garg AD, Dudek AM, Ferreira GB, Verfaillie T, Vandenabeele P, Krysko DV, Mathieu C, Agostinis P. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 2013; 9: 1292-307; PMID: 23800749; http://dx. doi. org/10. 4161/auto. 25399.
69. Garg AD, Agostinis P. ER stress, autophagy and immunogenic cell death in photodynamic therapyinduced anti-cancer immune responses. Photochem Photobiol Sci 2014; 13: 474-87; PMID: 24493131; http://dx. doi. org/10. 1039/c3pp50333j.
70. Garg AD, Dudek AM, Agostinis P. Autophagydependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity. Oncoimmunology 2013; 2: e26260; http://dx. doi. org/10. 4161/onci. 26260.
71. Korbelik M, Sun J, Cecic I. Photodynamic therapyinduced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 2005; 65: 1018-26; PMID: 15705903.
72. Panzarini E, Inguscio V, Dini L. Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int 2013; 2013: 482160; PMID: 23509727; http://dx. doi. org/10. 1155/2013/482160.
73. Yu P, Fu YX. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev 2008; 19: 285-94; PMID: 18508404; http://dx. doi. org/10. 1016/j. cytogfr. 2008. 04. 004.
74. Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, Fialova A, Sojka L, Cartron PF, Houska M, et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer 2014; 135: 1165-77; PMID: 24500981; http://dx. doi. org/10. 1002/ijc. 28766.
75. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3: 28694; PMID: 25097804; http://dx. doi. org/10. 4161/onci. 28694.
76. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2013; 2: e24612; PMID: 23894720; http://dx. doi. org/10. 4161/onci. 24612.
77. Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T, Aprahamian M, Bour G, Rüffer S, Cziepluch C, et al. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol 2014; 88: 5263-76; PMID: 24574398; http://dx. doi. org/10. 1128/JVI. 03688-13.
78. Workenhe ST, Mossman KL. Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. Oncoimmunology 2013; 2: e27138; http://dx. doi. org/10. 4161/onci. 27138.
79. Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol Res 2013; 1: 309-19; PMID: 24777969; http://dx. doi. org/10. 1158/2326-6066. CIR-13-0059-T.
80. Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 2013; 12: 103; PMID: 24020520; http://dx. doi. org/10. 1186/1476-4598-12-103.
81. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol 2014; 4: 74; PMID: 24782985; http://dx. doi. org/10. 3389/fonc. 2014. 00074.
82. Huang B, Sikorski R, Kirn DH, Thorne SH. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther 2011; 18: 164-72; PMID: 20 739958; http://dx. doi. org/10. 1038/gt. 2010. 121.
83. Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, Hemminki O, Diaconu I, Pesonen S, Koski A, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013; 21: 1212-23; PMID: 23546299; http://dx. doi. org/10. 1038/mt. 2013. 51.
84. Mineharu Y, King GD, Muhammad AK, Bannykh S, Kroeger KM, Liu C, Lowenstein PR, Castro MG. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res 2011; 17: 4705-18; PMID: 21632862; http://dx. doi. org/10. 1158/1078-0432. CCR-11-0915.
85. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007; 109: 4839-45; PMID: 17299090; http://dx. doi. org/10. 1182/blood-2006-10-054221.
86. Demaria S, Santori FR, Ng B, Liebes L, Formenti SC, Vukmanovic S. Select forms of tumor cell apoptosis induce dendritic cell maturation. J Leukoc Biol 2005; 77: 361-8; PMID: 15569694; http://dx. doi. org/10. 1189/jlb. 0804478.
87. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, Gonnella R, Frati L, Faggioni A. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One 2012; 7: e31732; PMID: 22412839; http://dx. doi. org/10. 1371/journal. pone. 0031732.
88. Chen HM, Wang PH, Chen SS, Wen CC, Chen YH, Yang WC, Yang NS. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cellbased cancer vaccine. Cancer Immunol Immunother 2012; 61: 1989-2002; PMID: 22527248; http://dx. doi. org/10. 1007/s00262-012-1258-9.
89. Garrido G, Rabasa A, Sanchez B, Lopez MV, Blanco R, Lopez A, Hernéandez DR, Péerez R, Fernéandez LE. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol 2011; 187: 4954-66; PMID: 21984704; http://dx. doi. org/10. 4049/jimmunol. 1003477.
90. D'Eliseo D, Manzi L, Velotti F. Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells. Cell Stress Chaperones 2013; 18: 801-8; http://dx. doi. org/10. 1007/s12192-013-0422-2.
91. Gilardini Montani MS, D'Eliseo D, Cirone M, Di Renzo L, Faggioni A, Santoni A, et al. Capsaicinmediated apoptosis of human bladder cancer cells activates dendritic cells via CD91. Nutrition 2014; In Press; PMID 25220876; http://dx. doi: 10. 1016/j. nut. 2014. 05. 005.
92. Molinari R, D'Eliseo D, Manzi L, Zolla L, Velotti F, Merendino N. The n3-polyunsaturated fatty acid docosahexaenoic acid induces immunogenic cell death in human cancer cell lines via pre-apoptotic calreticulin exposure. Cancer Immunol Immunother 2011; 60: 1503-7; PMID: 21779875; http://dx. doi. org/10. 1007/s00262-011-1074-7.
93. Emeagi PU, Van Lint S, Goyvaerts C, Maenhout S, Cauwels A, McNeish IA, Bos T, Heirman C, Thielemans K, Aerts JL, et al. Proinflammatory characteristics of SMACDIABLO-induced cell death in antitumor therapy. Cancer Res 2012; 72: 1342-52; PMID: 22379024; http://dx. doi. org/10. 1158/0008-5472. CAN-11-2400.
94. Emeagi PU, Thielemans K, Breckpot K. The role of SMAC mimetics in regulation of tumor cell death and immunity. Oncoimmunology 2012; 1: 965-7; PMID: 23162773; http://dx. doi. org/10. 4161/onci. 20369.
95. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012; 4: 143ra99; PMID: 22814852; http://dx. doi. org/10. 1126/scitranslmed. 3003807.
96. Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Sukkurwala AQ, Michaud M, Galluzzi L, Zitvogel L, et al. Anticancer activity of cardiac glycosides: at the frontier between cell-autonomous and immunological effects. Oncoimmunology 2012; 1: 1640-2; PMID: 23264921; http://dx. doi. org/10. 4161/onci. 21684.
97. Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology 2013; 2: e23082; PMID: 23525565; http://dx. doi. org/10. 4161/onci. 23082.
98. Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, Bosia A, Ghigo D, Massaia M. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One 2013; 8: e60975; PMID: 23593363; http://dx. doi. org/10. 1371/journal. pone. 0060975.
99. Riganti C, Massaia M. Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells: Killing two birds with one stone. Oncoimmunology 2013; 2: e25770; http://dx. doi. org/10. 4161/onci. 25770.
100. Liljenfeldt L, Gkirtzimanaki K, Vyrla D, Svensson E, Loskog AS, Eliopoulos AG. Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand. Cancer Immunol Immunother 2014; 63: 273-82; PMID: 24357147; http://dx. doi. org/10. 1007/s00262-013-1507-6.
101. Palombo F, Focaccetti C, Barnaba V. Therapeutic implications of immunogenic cell death in human cancer. Front Immunol 2014; 4: 503; PMID: 24432020; http://dx. doi. org/10. 3389/fimmu. 2013. 00503.
102. Olsson L, Ebbesen P. Experimental induction of tumor growth control by immune adjuvants: current status and some theories to be explored. Biomedicine 1978; 28: 88-91; PMID: 667279.
103. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5; PMID: 11951032; http://dx. doi. org/10. 1126/science. 1071059.
104. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39: 74-88; PMID: 23890065; http://dx. doi. org/10. 1016/j. immuni. 2013. 06. 014.
105. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 215-33; PMID: 22301798; http://dx. doi. org/10. 1038/nrd3626.
106. Ghiringhelli F, Apetoh L. The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. Expert Rev Clin Immunol 2014; 10: 19-30; PMID: 24308838; http://dx. doi. org/10. 1586/1744666X. 2014. 865520.
107. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4; PMID: 17008531; http://dx. doi. org/10. 1126/science. 1129139.
108. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306; PMID: 22419253; http://dx. doi. org/10. 1038/nrc3245.
109. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautèes-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1: 1323-43; PMID: 23243596; http://dx. doi. org/10. 4161/onci. 22009.
110. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al. Towards the introduction of the 'immunoscore' in the classification of malignant tumours. J Pathol 2014; 232: 199-209; PMID: 24122236; http://dx. doi. org/10. 1002/path. 4287.
111. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39: 782-95; PMID: 24138885; http://dx. doi. org/10. 1016/j. immuni. 2013. 10. 003.
112. AniteiMG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, BindeaG, Ferariu D, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res 2014; 20: 1891-9; PMID: 24691640; http://dx. doi. org/10. 1158/1078-0432. CCR-13-2830.
113. Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology 2014; 3: e27456; PMID: 24800163; http://dx. doi. org/10. 4161/onci. 27456.
114. Paroli M, Bellati F, Videtta M, Focaccetti C, Mancone C, Donato T, Antonilli M, Perniola G, Accapezzato D, Napoletano C, et al. Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells. Int J Cancer 2014; 134: 1823-34; PMID: 24150888; http://dx. doi. org/10. 1002/ijc. 28515.
115. Kohles N, Nagel D, Jungst D, Stieber P, Holdenrieder S. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumour Biol 2012; 33: 2401-9; PMID: 22965881; http://dx. doi. org/10. 1007/s13277-012-0504-2.
116. Stoetzer OJ, Wittwer C, Lehner J, Fahmueller YN, Kohles N, Fersching DM, Leszinski G, Roessner J, Holdenrieder S. Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy. Expert Opin Biol Ther 2012; 12 Suppl 1: S217-24; PMID: 22620489; http://dx. doi. org/10. 1517/14712598. 2012. 689280.
117. Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer 2013; 133: 2619-30; PMID: 23729200; http://dx. doi. org/10. 1002/ijc. 28294.
118. Stoll G, Enot D, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology 2014; 3: e27884; http://dx. doi. org/10. 4161/onci. 27884.
119. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-8; PMID: 19767732; http://dx. doi. org/10. 1038/nm. 2028.
120. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, Coudert B, Martin F, Bizollon MH, Vanoli A, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011; 224: 389-400; PMID: 21437909; http://dx. doi. org/10. 1002/path. 2866.
121. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010; 140: 798-804; PMID: 20303871; http://dx. doi. org/10. 1016/j. cell. 2010. 02. 015.
122. Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis 2013; 4: e631; PMID: 23681226; http://dx. doi. org/10. 1038/cddis. 2013. 156.
123. Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 2013; 39: 355-67; PMID: 23900966; http://dx. doi. org/10. 1002/biof. 1125.
124. Hou W, Zhang Q, Yan Z, Chen R, Zeh Iii HJ, Kang R, Lotze MT, Tang D. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis 2013; 4: e966; PMID: 24336086; http://dx. doi. org/10. 1038/cddis. 2013. 493.
125. Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 2014; 21: 26-38; PMID: 23686135; http://dx. doi. org/10. 1038/cdd. 2013. 48.
126. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53-71; PMID: 19720113; http://dx. doi. org/10. 1016/j. bbcan. 2009. 08. 003.
127. Honeychurch J, Dive C, Illidge TM. Synchronous apoptosis in established tumors leads to the induction of adaptive immunity. Oncoimmunology 2013; 2: e24501; http://dx. doi. org/10. 4161/onci. 24501.
128. Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 2014; 21: 39-49; http://dx. doi. org/10. 1038/cdd. 2013. 84.
129. Melis MH, Simpson KL, Dovedi SJ, Welman A, MacFarlane M, Dive C, Honeychurch J, Illidge TM. Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response. Cell Death Differ 2013; 20: 765-73; PMID: 23412345; http://dx. doi. org/10. 1038/cdd. 2013. 8.
130. Matzinger P. An innate sense of danger. Ann N Y Acad Sci 2002; 961: 341-2; PMID: 12081934; http://dx. doi. org/10. 1111/j. 1749-6632. 2002. tb03118. x.
131. Lotze MT, Deisseroth A, Rubartelli A. Damage associated molecular pattern molecules. Clin Immunol 2007; 124: 1-4; PMID: 17468050; http://dx. doi. org/10. 1016/j. clim. 2007. 02. 006.
132. Pouwels SD, Heijink IH, ten Hacken NH, Vandenabeele P, Krysko DV, Nawijn MC, van Oosterhout AJ. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol 2014; 7: 215-26; PMID: 24150257; http://dx. doi. org/10. 1038/mi. 2013. 77.
133. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004; 4: 469-78; PMID: 15173835; http://dx. doi. org/10. 1038/nri1372.
134. Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res 2007; 67: 7941-4; PMID: 17804698; http://dx. doi. org/10. 1158/0008-5472. CAN-07-1622.
135. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, Menger L, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30: 61-9; PMID: 21249425; http://dx. doi. org/10. 1007/s10555-011-9273-4.
136. Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev 2013; 24: 311-8; PMID: 23787159; http://dx. doi. org/10. 1016/j. cytogfr. 2013. 05. 001.
137. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, Séeror C, Méetivier D, Perfettini JL, Zitvogel L, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8: 3723-8; PMID: 19855167; http://dx. doi. org/10. 4161/cc. 8. 22. 10026.
138. Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S, Kepp O, Menger L, Vacchelli E, Galluzzi L, et al. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 2012; 8: 413-5; PMID: 22361584; http://dx. doi. org/10. 4161/auto. 19009.
139. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573-7; PMID: 22174255; http://dx. doi. org/10. 1126/science. 1208347.
140. Wang Y, Martins I, Ma Y, Kepp O, Galluzzi L, Kroemer G. Autophagy-dependent ATP release from dying cells via lysosomal exocytosis. Autophagy 2013; 9: 1624-5; PMID: 23989612; http://dx. doi. org/10. 4161/auto. 25873.
141. Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E, et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2013; 2: e24568; PMID: 23894718; http://dx. doi. org/10. 4161/onci. 24568.
142. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Méetivier D, Galluzzi L, Perfettini JL, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014; 21: 79-91; PMID: 23852373; http://dx. doi. org/10. 1038/cdd. 2013. 75.
143. Lavieri R, Piccioli P, Carta S, Delfino L, Castellani P, Rubartelli A. TLR costimulation causes oxidative stress with unbalance of proinflammatory and antiinflammatory cytokine production. J Immunol 2014; 192: 5373-81; PMID: 24771848; http://dx. doi. org/10. 4049/jimmunol. 1303480.
144. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Müller S, Iannacone M, Traversari C, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5: 825-30; PMID: 15272298; http://dx. doi. org/10. 1038/sj. embor. 7400205.
145. Brusa D, Migliore E, Garetto S, Simone M, Matera L. Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells. Prostate 2009; 69: 1343-52; PMID: 19496055; http://dx. doi. org/10. 1002/pros. 20981.
146. Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, GnantM, Bergmann M, Bachleitner-Hofmann T, et al. Plasma HMGB-1 after the initial dose of epirubicindocetaxel in cancer. Eur J Clin Invest 2013; 43: 286-91; PMID: 23410002; http://dx. doi. org/10. 1111/eci. 12043.
147. Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, Puntel M, Kroeger KM, Liu C, Lee S, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 2009; 15: 4401-14; PMID: 19570774; http://dx. doi. org/10. 1158/1078-0432. CCR-09-0155.
148. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 1249-55; PMID: 10545990; http://dx. doi. org/10. 1038/15200.
149. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13: 114-9; PMID: 11154927; http://dx. doi. org/10. 1016/S0952-7915(00)00191-6.
150. Fredly H, Ersvaer E, Gjertsen BT, Bruserud O. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 2011; 25: 1549-56; PMID: 21431284.
151. Aguilera R, Saffie C, Tittarelli A, Gonzalez FE, Ramirez M, Reyes D, Pereda C, Hevia D, Garclıa T, Salazar L, et al. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 2011; 17: 2474-83; PMID: 21292818; http://dx. doi. org/10. 1158/1078-0432. CCR-10-2384.
152. Lv LH, Wan YL, Lin Y, Zhang W, Yang M, Li GL, Lin HM, Shang CZ, Chen YJ, Min J. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem 2012; 287: 15874-85; PMID: 22396543; http://dx. doi. org/10. 1074/jbc. M112. 340588.
153. Vega VL, Rodriguez-Silva M, Frey T, Gehrmann M, Diaz JC, Steinem C, Multhoff G, Arispe N, De Maio A. Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J Immunol 2008; 180: 4299-307; PMID: 18322243; http://dx. doi. org/10. 4049/jimmunol. 180. 6. 4299.
154. Korbelik M, Banath J, Sun J, Canals D, Hannun YA, Separovic D. Ceramide and sphingosine-1-phosphate act as photodynamic therapy-elicited damage-associated molecular patterns: cell surface exposure. Int Immunopharmacol 2014; 20: 359-65; PMID: 24713544; http://dx. doi. org/10. 1016/j. intimp. 2014. 03. 016.
155. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13: 780-8; PMID: 23175281; http://dx. doi. org/10. 1038/nrm3479.
156. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, Vandenabeele P. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32: 157-64; PMID: 21334975; http://dx. doi. org/10. 1016/j. it. 2011. 01. 005.
157. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104-7; PMID: 20203610; http://dx. doi. org/10. 1038/nature08780.
158. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41; PMID: 16407889; http://dx. doi. org/10. 1038/nature04516.
159. Shi Y, Mucsi AD, Ng G. Monosodium urate crystals in inflammation and immunity. Immunol Rev 2010; 233: 203-17; PMID: 20193001; http://dx. doi. org/10. 1111/j. 0105-2896. 2009. 00851. x.
160. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009; 10: 241-7; PMID: 19221555; http://dx. doi. org/10. 1038/ni. 1703.
161. Ahrens S, Zelenay S, Sancho D, Hanc P, Kjaer S, Feest C, Fletcher G, Durkin C, Postigo A, Skehel M, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 2012; 36: 635-45; PMID: 22483800; http://dx. doi. org/10. 1016/j. immuni. 2012. 03. 008.
162. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004; 279: 17079-84; PMID: 14764599; http://dx. doi. org/10. 1074/jbc. M310859200.
163. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006; 177: 1272-81; PMID: 16818787; http://dx. doi. org/10. 4049/jimmunol. 177. 2. 1272.
164. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008; 20: 504-11; PMID: 18573340; http://dx. doi. org/10. 1016/j. coi. 2008. 05. 007.
165. Sonnemann J, Gressmann S, Becker S, Wittig S, Schmudde M, Beck JF. The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer Chemother Pharmacol 2010; 66: 611-6; PMID: 20221600; http://dx. doi. org/10. 1007/s00280-010-1302-4.
166. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2: 63ra94; PMID: 21178137; http://dx. doi. org/10. 1126/scitranslmed. 3001375.
167. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14: 303-13; PMID: 11290339; http://dx. doi. org/10. 1016/S1074-7613(01)00111-X.
168. Lauber K, Ernst A, Orth M, Herrmann M, Belka C. Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol 2012; 2: 116; PMID: 22973558; http://dx. doi. org/10. 3389/fonc. 2012. 00116.
169. Krysko DV, Vandenabeele P. Clearance of dead cells: mechanisms, immune responses and implication in the development of diseases. Apoptosis 2010; 15: 995-7; PMID: 20645005; http://dx. doi. org/10. 1007/s10495-010-0524-6.
170. Krysko DV, Vanden Berghe T, Parthoens E, D'Herde K, Vandenabeele P. Methods for distinguishing apoptotic from necrotic cells and measuring their clearance. Methods Enzymol 2008; 442: 307-41; PMID: 18662577; http://dx. doi. org/10. 1016/S0076-6879(08)01416-X.
171. Krysko DV, Vandenabeele P. From regulation of dying cell engulfment to development of anti-cancer therapy. Cell Death Differ 2008; 15: 29-38; PMID: 18007662; http://dx. doi. org/10. 1038/sj. cdd. 4402271.
172. Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006; 11: 1709-26; PMID: 16951923; http://dx. doi. org/10. 1007/s10495-006-9527-8.
173. Weiss EM, Frey B, Rodel F, Herrmann M, Schlucker E, Voll RE, Fietkau R, Gaipl US. Ex vivo-and in vivo-induced dead tumor cells as modulators of antitumor responses. Ann N Y Acad Sci 2010; 1209: 109-17; PMID: 20958323; http://dx. doi. org/10. 1111/j. 1749-6632. 2010. 05743. x.
174. Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER, Armstrong AJ, Penuela S, Laird DW, Salvesen GS, et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 2010; 467: 863-7; PMID: 20944749; http://dx. doi. org/10. 1038/nature09413.
175. Ayna G, Krysko DV, Kaczmarek A, Petrovski G, Vandenabeele P, Fesus L. ATP release from dying autophagic cells and their phagocytosis are crucial for inflammasome activation in macrophages. PLoS One 2012; 7: e40069; PMID: 22768222; http://dx. doi. org/10. 1371/journal. pone. 0040069.
176. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology 2012; 1: 786-8; PMID: 22934283; http://dx. doi. org/10. 4161/onci. 19750.
177. ElliottMR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461: 282-6; PMID: 19741708; http://dx. doi. org/10. 1038/nature08296.
178. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapyinduced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38: 729-41; PMID: 23562161; http://dx. doi. org/10. 1016/j. immuni. 2013. 03. 003.
179. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, Beck PL, Muruve DA, Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010; 330: 362-6; PMID: 20947763; http://dx. doi. org/10. 1126/science. 1195491.
180. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, Smyth MJ, Zitvogel L. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70: 855-8; PMID: 20086177; http://dx. doi. org/10. 1158/0008-5472. CAN-09-3566.
181. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci 2007; 28: 465-72; PMID: 17692395; http://dx. doi. org/10. 1016/j. tips. 2007. 07. 002.
182. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L, Kanellopoulos J, Quesniaux VF, Marchand-Adam S, Crestani B, et al. Extracellular ATP is a danger signal activating P2´7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 2010; 182: 774-83; PMID: 20522787; http://dx. doi. org/10. 1164/rccm. 201003-0359OC.
183. Cauwels A, Rogge E, Vandendriessche B, Shiva S, Brouckaert P. Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell Death Dis 2014; 5: e1102; http://dx. doi. org/10. 1038/cddis. 2014. 70.
184. Xiang Y, Wang X, Yan C, Gao Q, Li SA, Liu J, Zhou K, Guo X, Lee W, Zhang Y. Adenosine-50-triphosphate (ATP) protects mice against bacterial infection by activation of the NLRP3 inflammasome. PLoS One 2013; 8: e63759; PMID: 23717478; http://dx. doi. org/10. 1371/journal. pone. 0063759.
185. Gombault A, Baron L, Couillin I. ATP release and purinergic signaling in NLRP3 inflammasome activation. Front Immunol 2012; 3: 414; PMID: 23316199; http://dx. doi. org/10. 3389/fimmu. 2012. 00414.
186. Riteau N, Baron L, Villeret B, Guillou N, Savigny F, Ryffel B, Rassendren F, Le Bert M, Gombault A, Couillin I. ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation. Cell Death Dis 2012; 3: e403; PMID: 23059822; http://dx. doi. org/10. 1038/cddis. 2012. 144.
187. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, Eisenbarth SC, Florquin S, Flavell RA, Leemans JC, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A 2009; 106: 20388-93; PMID: 19918053; http://dx. doi. org/10. 1073/pnas. 0908698106.
188. England H, Summersgill HR, Edye ME, Rothwell NJ, Brough D. Release of interleukin-1alpha or interleukin-1beta depends on mechanism of cell death. J Biol Chem 2014; 289: 15942-50; PMID: 24790078; http://dx. doi. org/10. 1074/jbc. M114. 557561.
189. Steer SA, Scarim AL, Chambers KT, Corbett JA. Interleukin-1 stimulates beta-cell necrosis and release of the immunological adjuvant HMGB1. PLoS Med 2006; 3: e17; http://dx. doi. org/10. 1371/journal. pmed. 0030017.
190. Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L, Kroemer G. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology 2012; 1: 393-5; PMID: 22737627; http://dx. doi. org/10. 4161/onci. 19070.
191. Aliagas E, Vidal A, Texido L, Ponce J, Condom E, Martin-Satue M. High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. Mediators Inflamm 2014; 2014: 509027; PMID: 24707115; http://dx. doi. org/10. 1155/2014/509027.
192. Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, Stagg J. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A 2013; 110: 11091-6; PMID: 23776241; http://dx. doi. org/10. 1073/pnas. 1222251110.
193. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013; 19: 355-67; PMID: 23601906; http://dx. doi. org/10. 1016/j. molmed. 2013. 03. 005.
194. Ghiringhelli F, Bruchard M, Chalmin F, Rebe C. Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol 2012; 2012: 473712; PMID: 23133312; http://dx. doi. org/10. 1155/2012/473712.
195. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A. ENTPD1CD39 is a promising therapeutic target in oncology. Oncogene 2013; 32: 1743-51; PMID: 22751118; http://dx. doi. org/10. 1038/onc. 2012. 269.
196. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011; 187: 676-83; PMID: 21677139; http://dx. doi. org/10. 4049/jimmunol. 1003884.
197. Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, Sykacek P, Frank L, Schramek D, Komnenovic V, et al. A dual role for autophagy in a murine model of lung cancer. Nat Commun 2014; 5: 3056; PMID: 24445999; http://dx. doi. org/10. 1038/ncomms4056.
198. Senovilla L, Aranda F, Galluzzi L, Kroemer G. Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr Opin Immunol 2014; 30C: 24-31; PMID: 24950501; http://dx. doi. org/10. 1016/j. coi. 2014. 05. 009.
199. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. Immunity 2013; 39: 211-27; PMID: 23973220; http://dx. doi. org/10. 1016/j. immuni. 2013. 07. 017.
200. Li H, Li Y, Jiao J, Hu HM. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol 2011; 6: 645-50; PMID: 21926980; http://dx. doi. org/10. 1038/nnano. 2011. 153.
201. Thorburn J, Horita H, Redzic J, Hansen K, Frankel AE, Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ 2009; 16: 175-83; PMID: 18846108; http://dx. doi. org/10. 1038/cdd. 2008. 143.
202. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5; PMID: 12110890; http://dx. doi. org/10. 1038/nature00858.
203. Park JS, Gamboni-Robertson F, HeQ, SvetkauskaiteD, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290: C917-24; PMID: 16267105; http://dx. doi. org/10. 1152/ajpcell. 00401. 2005.
204. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006; 26: 174-9; PMID: 16878026; http://dx. doi. org/10. 1097/01. shk. 0000225404. 51320. 82.
205. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-42; PMID: 15803152; http://dx. doi. org/10. 1038/nri1594.
206. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61: 1-9; PMID: 15644117; http://dx. doi. org/10. 1111/j. 0300-9475. 2005. 01534. x.
207. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007; 30: 596-606; PMID: 17667523; http://dx. doi. org/10. 1097/CJI. 0b 013e31804efc76.
208. Pathak SK, Skold AE, Mohanram V, Persson C, Johansson U, Spetz AL. Activated apoptotic cells induce dendritic cell maturation via engagement of Toll-like receptor 4 (TLR4), dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN), and beta2 integrins. J Biol Chem 2012; 287: 13731-42; PMID: 22396536; http://dx. doi. org/10. 1074/jbc. M111. 336545.
209. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35-46; PMID: 17979838; http://dx. doi. org/10. 1111/j. 1600-065X. 2007. 00574. x.
210. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009; 6: e10; http://dx. doi. org/10. 1371/journal. pmed. 1000010.
211. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, Apuzzo T, De Marchis F, Pedotti M, Bachi A, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012; 209: 551-63; PMID: 22370717; http://dx. doi. org/10. 1084/jem. 20111739.
212. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ 3rd, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010; 190: 881-92; PMID: 20819940; http://dx. doi. org/10. 1083/jcb. 200911078.
213. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011; 18: 571-80; PMID: 21311563; http://dx. doi. org/10. 1038/cdd. 2010. 191.
214. Kang R, Livesey KM, Zeh HJ, 3rd, Lotze MT, Tang D. HMGB1 as an autophagy sensor in oxidative stress. Autophagy 2011; 7: 904-6; PMID: 21487246; http://dx. doi. org/10. 4161/auto. 7. 8. 15704.
215. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME, Al-Abed Y, Andersson U, Tracey KJ, Antoine DJ, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012; 18: 250-9; PMID: 22105604; http://dx. doi. org/10. 2119/molmed. 2011. 00389.
216. Tang D, Billiar TR, Lotze MT. A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med 2012; 18: 1360-2; PMID: 23073660; http://dx. doi. org/10. 2119/molmed. 2012. 00314.
217. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, Liu J, Antonelli A, Preti A, Raeli L, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012; 209: 1519-28; PMID: 22869893; http://dx. doi. org/10. 1084/jem. 20120189.
218. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29: 5299-310; PMID: 20622903; http://dx. doi. org/10. 1038/onc. 2010. 261.
219. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29: 21-32; PMID: 18631454; http://dx. doi. org/10. 1016/j. immuni. 2008. 05. 013.
220. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007; 28: 429-36; PMID: 17845865; http://dx. doi. org/10. 1016/j. it. 2007. 08. 004.
221. Urbonaviciute V, Meister S, Furnrohr BG, Frey B, Guckel E, Schett G, Herrmann M, Voll RE. Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. Autoimmunity 2009; 42: 305-7; PMID: 19811284; http://dx. doi. org/10. 1080/08916930902831803.
222. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13: 832-42; PMID: 22842346; http://dx. doi. org/10. 1038/ni. 2376.
223. Tang D, Lotze MT. Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol 2012; 13: 808-10; PMID: 22910384; http://dx. doi. org/10. 1038/ni. 2396.
224. Patel J, Bozeman EN, Selvaraj P. Taming dendritic cells with TIM-3: another immunosuppressive strategy used by tumors. Immunotherapy 2012; 4: 1795-8; PMID: 23240746; http://dx. doi. org/10. 2217/imt. 12. 126.
225. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1: 894-907; PMID: 23162757; http://dx. doi. org/10. 4161/onci. 20931.
226. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, lluzzi L. Trial watch: tolllike receptor agonists for cancer therapy. Oncoimmunology 2013; 2: e25238; http://dx. doi. org/10. 4161/onci. 25238.
227. Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2014; 21: 69-78; PMID: 23811849; http://dx. doi. org/10. 1038/cdd. 2013. 72.
228. Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, et al. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3: e29179; http://dx. doi. org/10. 4161/onci. 29179.
229. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59; PMID: 17979839; http://dx. doi. org/10. 1111/j. 1600-065X. 2007. 00573. x.
230. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208: 491-503; PMID: 21383056; http://dx. doi. org/10. 1084/jem. 20100269.
231. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445-544; PMID: 22966490; http://dx. doi. org/10. 4161/auto. 19496.
232. Sukkurwala AQ, Adjemian S, Senovilla L, Michaud M, Spaggiari S, Vacchelli E, Baracco EE, Galluzzi L, Zitvogel L, Kepp O, et al. Screening of novel immunogenic cell death inducers within the NCI mechanistic diversity set. Oncoimmunology 2014; 3: e28473; http://dx. doi. org/10. 4161/onci. 28473.
233. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-71; PMID: 21219185; http://dx. doi. org/10. 1146/annurev-immunol-031210-101324.
234. Zirger JM, Puntel M, Bergeron J, Wibowo M, Moridzadeh R, Bondale N, Barcia C, Kroeger KM, Liu C, Castro MG, et al. Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNgamma, perforin, and TNFalpha, and due to the elimination of transduced cells. Mol Ther 2012; 20: 808-19; PMID: 22233583; http://dx. doi. org/10. 1038/mt. 2011. 243.
235. Tailler M, Senovilla L, Lainey E, Thepot S, Metivier D, Sebert M, Baud V, Billot K, Fenaux P, Galluzzi L, et al. Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene 2012; 31: 3536-46; PMID: 22105358; http://dx. doi. org/10. 1038/onc. 2011. 521.
236. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10: 221-37; PMID: 21358741; http://dx. doi. org/10. 1038/nrd3373.
237. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 1995; 184: 39-51; PMID: 7622868; http://dx. doi. org/10. 1016/0022-1759(95)00072-I.
238. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-20; PMID: 8068938.
239. Galluzzi L, Vitale I, Kepp O, Seror C, Hangen E, Perfettini JL, Modjtahedi N, Kroemer G. Methods to dissect mitochondrial membrane permeabilization in the course of apoptosis. Methods Enzymol 2008; 442: 355-74; PMID: 18662579; http://dx. doi. org/10. 1016/S0076-6879(08)01418-3.
240. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 2007; 12: 803-13; PMID: 17294081; http://dx. doi. org/10. 1007/s10495-007-0720-1.
241. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX, Kroemer G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995; 181: 1661-72; PMID: 7722446; http://dx. doi. org/10. 1084/jem. 181. 5. 1661.
242. Mellen MA, de la Rosa EJ, Boya P. Autophagy is not universally required for phosphatidyL-serine exposure and apoptotic cell engulfment during neural development. Autophagy 2009; 5: 964-72; PMID: 19587526; http://dx. doi. org/10. 4161/auto. 5. 7. 9292.
243. Mellen MA, de la Rosa EJ, Boya P. The autophagic machinery is necessary for removal of cell corpses from the developing retinal neuroepithelium. Cell Death Differ 2008; 15: 1279-90; PMID: 18369370; http://dx. doi. org/10. 1038/cdd. 2008. 40.
244. Segawa K, Kurata S, Yanagihashi Y, Brummelkamp TR, Matsuda F, Nagata S. Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science 2014; 344: 1164-8; PMID: 24904167; http://dx. doi. org/10. 1126/science. 1252809.
245. Kenis H, Zandbergen HR, Hofstra L, Petrov AD, Dumont EA, Blankenberg FD, Haider N, Bitsch N, Gijbels M, Verjans JW, et al. Annexin A5 uptake in ischemic myocardium: demonstration of reversible phosphatidylserine externalization and feasibility of radionuclide imaging. J Nucl Med 2010; 51: 259-67; PMID: 20124049; http://dx. doi. org/10. 2967/jnumed. 109. 068429.
246. Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. Circ Res 2012; 111: 1198-207; PMID: 23065343; http://dx. doi. org/10. 1161/CIRCR ESAHA. 112. 268946.
247. Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci 2009; 10: 481-94; PMID: 19543220; http://dx. doi. org/10. 1038/nrn2665.
248. Metivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I, Kroemer G. Cytofluorometric detection of mitochondrial alterations in early CD95FasAPO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrionspecific fluorochromes. Immunol Lett 1998; 61: 157-63; PMID: 9657269; http://dx. doi. org/10. 1016/S0165-2478(98)00013-3.
249. Komoriya A, Packard BZ, Brown MJ, Wu ML, Henkart PA. Assessment of caspase activities in intact apoptotic thymocytes using cell-permeable fluorogenic caspase substrates. J Exp Med 2000; 191: 1819-28; PMID: 10839799; http://dx. doi. org/10. 1084/jem. 191. 11. 1819.
250. Kepp O, Rajalingam K, Kimmig S, Rudel T. Bak and Bax are non-redundant during infection-and DNA damage-induced apoptosis. EMBO J 2007; 26: 825-34; PMID: 17235284; http://dx. doi. org/10. 1038/sj. emboj. 7601533.
251. Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami N, et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008; 27: 4221-32; PMID: 18362892; http://dx. doi. org/10. 1038/onc. 2008. 63.
252. Pauleau AL, Larochette N, Giordanetto F, Scholz SR, Poncet D, Zamzami N, Goldmacher VS, Kroemer G. Structure-function analysis of the interaction between Bax and the cytomegalovirus-encoded protein vMIA. Oncogene 2007; 26: 7067-80; PMID: 17496930; http://dx. doi. org/10. 1038/sj. onc. 1210511.
253. Garg AD, Dudek AM, Agostinis P. Calreticulin surface exposure is abrogated in cells lacking, chaperonemediated autophagy-essential gene, LAMP2A. Cell Death Dis 2013; 4: e826; http://dx. doi. org/10. 1038/cddis. 2013. 372.
254. Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Discov 2013; 12: 703-19; PMID: 23989796; http://dx. doi. org/10. 1038/nrd3976.
255. Hetz C, Martinon F, Rodriguez D, Glimcher LH. The unfolded protein response: integrating stress signals through the stress sensor IRE1alpha. Physiol Rev 2011; 91: 1219-43; PMID: 22013210; http://dx. doi. org/10. 1152/physrev. 00001. 2011.
256. Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008; 8: 663-74; PMID: 18670423; http://dx. doi. org/10. 1038/nri2359.
257. Omasa T, Chen YG, Mantalaris A, Tsai YC, Wu JH. Molecular cloning and sequencing of the human heme-regulated eukaryotic initiation factor 2 alpha (eIF-2 alpha) kinase from bone marrow culture. DNA Seq 2002; 13: 133-7; PMID: 12391722.
258. Samuel CE. The eIF-2 alpha protein kinases, regulators of translation in eukaryotes from yeasts to humans. J Biol Chem 1993; 268: 7603-6; PMID: 8096514.
259. Shi Y, Vattem KM, Sood R, An J, Liang J, Stramm L, Wek RC. Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol 1998; 18: 7499-509; PMID: 9819435.
260. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999; 397: 271-4; PMID: 9930704; http://dx. doi. org/10. 1038/16729.
261. Yang Y, Li XJ, Chen Z, Zhu XX, Wang J, Zhang LB, Qiang L, Ma YJ, Li ZY, Guo QL, et al. Wogonin induced calreticulinannexin A1 exposure dictates the immunogenicity of cancer cells in a PERKAKT dependent manner. PLoS One 2012; 7: e50811; http://dx. doi. org/10. 1371/journal. pone. 0050811.
262. van Schadewijk A, van't Wout EF, Stolk J, Hiemstra PS. A quantitative method for detection of spliced Xbox binding protein-1 (XBP1) mRNA as a measure of endoplasmic reticulum (ER) stress. Cell Stress Chaperones 2012; 17: 275-9; PMID: 22038282; http://dx. doi. org/10. 1007/s12192-011-0306-2.
263. Hayashi A, Kasahara T, Iwamoto K, Ishiwata M, Kametani M, Kakiuchi C, Furuichi T, Kato T. The role of brain-derived neurotrophic factor (BDNF)-induced XBP1 splicing during brain development. J Biol Chem 2007; 282: 34525-34; PMID: 17890727; http://dx. doi. org/10. 1074/jbc. M704300200.
264. Prischi F, Nowak PR, Carrara M, Ali MM. Phosphoregulation of Ire1 RNase splicing activity. Nat Commun 2014; 5: 3554; PMID: 24704861; http://dx. doi. org/10. 1038/ncomms4554.
265. Reineke LC, Dougherty JD, Pierre P, Lloyd RE. Large G3BP-induced granules trigger eIF2alpha phosphorylation. Mol Biol Cell 2012; 23: 3499-510; PMID: 22833567; http://dx. doi. org/10. 1091/mbc. E12-05-0385.
266. Lundin A, Thore A. Analytical information obtainable by evaluation of the time course of firefly bioluminescence in the assay of ATP. Anal Biochem 1975; 66: 47-63; PMID: 1096673; http://dx. doi. org/10. 1016/0003-2697(75)90723-X.
267. McElroy WD, DeLuca MA. Firefly and bacterial luminescence: basic science and applications. J Appl Biochem 1983; 5: 197-209; PMID: 6680120.
268. Sorensen CE, Novak I. Visualization of ATP release in pancreatic acini in response to cholinergic stimulus. Use of fluorescent probes and confocal microscopy. J Biol Chem 2001; 276: 32925-32; PMID: 11387334; http://dx. doi. org/10. 1074/jbc. M103313200.
269. Imamura H, Nhat KP, Togawa H, Saito K, Iino R, Kato-Yamada Y, Nagai T, Noji H. Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc Natl Acad Sci U S A 2009; 106: 15651-6; PMID: 19720993; http://dx. doi. org/10. 1073/pnas. 0904764106.
270. Tasdemir E, Galluzzi L, Maiuri MC, Criollo A, Vitale I, Hangen E, Modjtahedi N, Kroemer G. Methods for assessing autophagy and autophagic cell death. Methods Mol Biol 2008; 445: 29-76; PMID: 18425442; http://dx. doi. org/10. 1007/978-1-59745-157-4_3.
271. Klionsky DJ. A human autophagy interaction network. Autophagy 2012; 8: 439-41; PMID: 22781101; http://dx. doi. org/10. 4161/auto. 19926.
272. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19: 5720-8; PMID: 11060023; http://dx. doi. org/10. 1093/emboj/19. 21. 5720.
273. Klionsky DJ. Autophagy in mammalian systems, part B. Preface. Methods Enzymol 2009; 452: xxi-xxii.
274. Mizushima N, Yamamoto A, Hatano M, Kobayashi Y, Kabeya Y, Suzuki K, Tokuhisa T, Ohsumi Y, Yoshimori T. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol 2001; 152: 657-68; PMID: 11266458; http://dx. doi. org/10. 1083/jcb. 152. 4. 657.
275. Martins I, Kepp O, Menger L, Michaud M, Adjemian S, Sukkurwala AQ, Vacchelli E, Galluzzi L, Kroemer G. Fluorescent biosensors for the detection of HMGB1 release. Methods Mol Biol 2013; 1004: 43-56; PMID: 23733568; http://dx. doi. org/10. 1007/978-1-62703-383-1_4.
276. Antoine DJ, Harris HE, Andersson U, Tracey KJ, Bianchi ME. A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins. Mol Med 2014; 20: 135-7; PMID: 24531895; http://dx. doi. org/10. 2119/molmed. 2014. 00022.
277. Perne A, Muellner MK, Steinrueck M, Craig-Mueller N, Mayerhofer J, Schwarzinger I, Sloane M, Uras IZ, Hoermann G, Nijman SM, et al. Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One 2009; 4: e8292; http://dx. doi. org/10. 1371/journal. pone. 0008292.
278. Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A 2011; 108: E1408-16; PMID: 22123951; http://dx. doi. org/10. 1073/pnas. 1115050108.
279. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 2012; 12: 786-98; PMID: 23059428; http://dx. doi. org/10. 1038/nri3311.
280. Payne KJ, Crooks GM. Immune-cell lineage commitment: translation from mice to humans. Immunity 2007; 26: 674-7; PMID: 17582340; http://dx. doi. org/10. 1016/j. immuni. 2007. 05. 011.
281. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, Saito Y, Marches F, Halene S, Palucka AK, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 2014; 32: 364-72; PMID: 24633240; http://dx. doi. org/10. 1038/nbt. 2858.
282. Ladoire S, Chaba K, Martins I, Sukkurwala AQ, Adjemian S, Michaud M, Poirier-Colame V, Andreiuolo F, Galluzzi L, White E, et al. Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy 2012; 8: 1175-84; PMID: 22647537; http://dx. doi. org/10. 4161/auto. 20353.
283. Ladoire S, Hannani D, Vetizou M, Locher C, Aymeric L, Apetoh L, Kepp O, Kroemer G, Ghiringhelli F, Zitvogel L. Cell-death-associated molecular patterns as determinants of cancer immunogenicity. Antioxid Redox Signal 2014; 20: 1098-116; PMID: 23394620; http://dx. doi. org/10. 1089/ars. 2012. 5133.
284. Zitvogel L, Tanchot C, Granier C, Tartour E. Following up tumor-specific regulatory T cells in cancer patients. Oncoimmunology 2013; 2: e25444; http://dx. doi. org/10. 4161/onci. 25444.
285. Popadic D, Anegon I, Baeten D, Eibel H, Giese T, Marits P, Martinez-Caceres E, Mascart F, Nestle F, Pujol-Borrell R, et al. Predictive immunomonitoring-the COST ENTIRE initiative. Clin Immunol 2013; 147: 23-6; PMID: 23454893; http://dx. doi. org/10. 1016/j. clim. 2013. 01. 013.
286. Jager M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Ströhlein M, Theissen B, Heiss MM, et al. Immunomonitoring results of a phase IIIII study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res 2012; 72: 24-32; PMID: 22044753; http://dx. doi. org/10. 1158/0008-5472. CAN-11-2235.
287. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-401; PMID: 11096443; http://dx. doi. org/10. 1089/104303400750038499.
288. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase geneGanciclovir system: fifteen years of application. CurrGene Ther 2003; 3: 13-26; PMID: 12553532; http://dx. doi. org/10. 2174/1566523033347426.